The European Patent Office has decided to grant Active Biotech’s patent application covering tasquinimod for use in the treatment of multiple myeloma.
The patent will be granted as European Patent No. 3041472 on February 1, 2017 and has a duration lasting until 2035, said the company.
Active Biotech about tasquinimod
Tasquinimod is an immunomodulatory, anti-metastatic and anti-angiogenic compound that affects the tumor’s ability to grow and spread. The development of tasquinimod has previously been focused on the treatment of prostate cancer with clinical proof of concept and a good safety profile shown in Phase 2 and 3 studies. Tasquinimod’s mechanism of action is broadly applicable as anti-tumor treatment and very good results have been achieved in models for multiple myeloma, a blood cancer with a high medical need. Active Biotech is seeking a partner for the continued development of tasquinimod in multiple myeloma.